1968 - 2020

Lupin commences business


Lupin Laboratories Pvt. Ltd. is incorporated


First Formulation Plant and R&D Center at Aurangabad is commissioned


Production of Ethambutol API starts


The Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar go on stream


Lupin Human Welfare and Research Foundation (LHWRF) is founded by Desh Bandhu Gupta


Joint Venture in Thailand is established

USFDA approvals for Ankleshwar and Mandideep plants received


Initiates production of Injectable Cephalosporins (API and Finished Product) at Mandideep


Fermentation Plant at Lupin Chemicals Ltd. Tarapur, Maharashtra established

Commissions Sterile Plant for Injectable Cephalosporins (API) at Mandideep


IPO of Lupin Laboratories Ltd. and Lupin Chemicals Ltd.


USFDA approval for Cefaclor at Mandideep, 7 ACCA at Ankleshwar and Rifampicin at Tarapur


UK MCA approval for the Injectable Cephalosporin Finished Product Plant at Mandideep


UK MCA approval for the Injectable Cephalosporin API plant at Mandideep


USFDA approval for Injectable Cefotaxime (API and Finished Product) at Mandideep


State-Of-The-Art R&D center, Lupin Research Park at Pune commissioned

Supply of Cephalosporin Finished Product to Alliance Partners in the US commences

Lupin Laboratories Ltd. is amalgamated with Lupin Chemicals Ltd., and retitled Lupin Ltd.


Exports to Advanced Markets cross INR 1000 Million

Patent filings cross 100

First 5 ANDAs filed

New Anti-TB Facility commissioned at Aurangabad

Rablet® rated by ORG-Marg as the second best launch in India in FY 2002-03


WHO approval for finished product facility at Aurangabad

SAP ERP implemented across the company to unify all business functions and processes

USFDA approval for the Oral Cephalosporin Plant at Mandideep

Lupin Pharmaceuticals Inc. USA, formed for commercialization activities in the US


Commences US Branded Business with the launch of Suprax®


Generics Business launched in the US with first 4 Products

USFDA approval for New Lovastatin Plant at Tarapur

USFDA approval for Goa finished product facility

Maiden Employees Stock Option Plan launched


UK MHRA and WHO approval for Goa finished product facility

Maiden bonus shares issued in the ratio of 1:1

Maiden Issue of Foreign Currency Convertible Bonds aggregating USD 100 Million


Acquired Kyowa Pharmaceutical Industry Company Ltd., a leading Generics Company in Japan

Vadodara based Rubamin Laboratories Ltd. acquired

Starts commercial production at the new finished product facility at Jammu


Biotech Facility in Pune set up

Acquired Hormosan Pharma Gmbh in Germany

Majority stake in Generic Health Pty Ltd., Australia acquired

Acquired majority stake in Pharma Dynamics, South Africa


Acquired the US Rights for Antara®

Majority stake in Multicare
Pharmaceuticals Philippines Inc. acquired

India Region Formulations (IRF) business crosses INR 1,000 Cr.


Commercial Production at the New Oral

Solid Dosage Facility at Pithampur commences

Acquires I’Rom Pharmaceuticals in Japan

India Formulations business inks its first in-license deal with Huminsulin®


Enters the Nifty 50 Index


Tonact® became the first Lupin brand to cross INR 100 Cr.


Joint Venture Agreement with Yoshindo Inc. in Japan to launch biosimilars

Acquires Laboratorios Grin, Mexico, Specialty Ophthalmic Company and with this enters the Latin American Market

Acquires Nanomi B.V. to enter the Complex Injectables Space


Center of Excellence for Inhalation Research in Coral Springs Florida inaugurated

Acquires Specialty Product Portfolio of Temmler Pharma GmbH & Co. in Germany

Acquires Medquimica Industria Farmaceutica S.A. in Brazil

Completes the acquisition of Pharma Dynamics in South Africa


India Formulations business crosses INR 3,000 Cr.

Bolsters the US Brands Portfolio with Methergine® Oral Tablets

Acquires Branded Product Portfolio from Shionogi & Co. Ltd. in Japan

Completes acquisition of US based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS)


Commissions new plant at Tottori, Japan

Forays into the OTC Segment with pan-India launch of Softovac®

Inaugurates a new plant at Sikkim

The number of sales representatives in India Formulations business crosses the 5,000 mark


Acquires Symbiomix Therapeutics, LLC in New Jersey for launch of Solosec®

Commissions Injectables Facility at Nagpur

Files New Drug Application for Etanercept Biosimilar in Japan

Signs deal with AbbVie for exclusive rights to develop and commercialize Lupin’s MALT1 inhibitors (oncology)


Inks partnership with Boehringer Ingelheim to develop and commercialize Lupin’s MEK inhibitors (oncology)

Orphan Drug NaMuscla® for treatment of non-dystrophic Myotonia launched in Europe


Receives European Marketing Authorization for Nepexto, Biosimilar Etanercept

Receives International Sustainability Rating System (ISRS) Certification for 4 sites


India Formulations business crosses INR 5,000 Cr.